ScreenerHero

CRL Charles River Laboratories International, Inc.

NYSE · US · Healthcare · Diagnostics & Research · criver.com
310.77USD+7.09%Mkt Cap: 14.84B $P/E: —

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Mode…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$250.23BUSDP/E 36.4
DHR
Danaher Corporation
$155.51BUSDP/E 39.4
NTRA
Natera, Inc.
$61.35BUSD
LONN
Lonza Group AG
$45.82BUSDP/E 38.1
A
Agilent Technologies, Inc.
$48.29BUSDP/E 33.8
ILMN
Illumina, Inc.
$44.35BUSDP/E 54.8
IQV
IQVIA Holdings Inc.
$43.80BUSDP/E 33.1
WAT
Waters Corporation
$43.21BUSDP/E 111.4
IDXX
IDEXX Laboratories, Inc.
$41.58BUSDP/E 37.0
MTD
Mettler-Toledo International Inc.
$30.89BUSDP/E 34.7
DGX
Quest Diagnostics Incorporated
$25.63BUSDP/E 24.7
GH
Guardant Health, Inc.
$25.12BUSD
LH
Labcorp Holdings Inc.
$25.03BUSDP/E 25.5
RVTY
Revvity, Inc.
$17.56BUSDP/E 75.3
MEDP
Medpace Holdings, Inc.
$17.32BUSDP/E 36.4
ERF
Eurofins Scientific SE
$14.05BUSDP/E 26.2
ICLR
ICON Public Limited Company
$12.99BUSDP/E 177.2
BIM
bioMérieux S.A.
$10.02BUSDP/E 20.0
QGEN
Qiagen N.V.
$9.46BUSDP/E 23.2
GRAL
GRAIL, Inc.
$6.88BUSD

Key Statistics

Company
Market Cap14.84B USD
Enterprise Value16.74B USD
Revenue (TTM)4.00B USD
Gross Profit1.32B USD
Net Income (TTM)-144.34M USD
Revenue/Share81.86 USD
Last Price310.77 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18.3K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)22.78
PEG0.12
EV/EBITDA19.72
EV/Revenue4.19
P/S3.46
P/B4.88
EPS (TTM)-4.80
EPS (Forward)12.74
52W Range
146.2099% of range312.05
52W High312.05 USD
52W Low146.20 USD
Profitability
Gross Margin32.96%
Oper. Margin15.11%
EBITDA Margin21.23%
Profit Margin-3.59%
ROE-4.56%
ROA-2.02%
Growth
Revenue Growth-2.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF737.65M USD
CapEx (TTM)219.15M USD
FCF Margin11.72%
FCF Yield3.16%
Net Debt2.84B USD
Net Debt/EBITDA3.35
Balance Sheet
Debt/Equity0.81
Current Ratio1.35
Quick Ratio0.80
Book Value/Sh59.50 USD
Cash/Share4.02 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)305.00 USD
Upside (mean)-1.9%
Target Range145.00 USD – 357.00 USD
145.00-1.9% to mean357.00
# Analysts15
Ownership
Shares Out.47.74M
Float47.22M
Insiders0.47%
Institutions122.80%
Short Interest
Short Ratio2.6d
Short % Float5.40%
Short % Out.4.67%
Shares Short2.23M
Short (prev mo.)2.36M
Technical
SMA 50276.07 (+12.6%)
SMA 200209.97 (+48.0%)
Beta1.41
S&P 52W Chg14.58%
Avg Vol (30d)912.11K
Avg Vol (10d)973.53K
Technical Indicators
RSI (14)67.4
MACD6.3011
MACD Signal5.1752
MACD Hist.+1.1259
BB Upper305.01 USD
BB Middle284.58 USD
BB Lower264.15 USD
BB Width14.36%
ATR (14)10.21 USD
Vol Ratio (20d)1.37x